Subject: Ovation Science Inc.
PDF Document
File: Attachment 261119_NRAdoptSemiAnnual v2.pdf
OVATION SCIENCE INC. ANNOUNCES ADOPTION OF SEMI-ANNUAL FINANCIAL REPORTING
Vancouver, BC, Las Vegas, NV November 19, 2026 Ovation Science Inc. (CSE: OVAT / OTC: OVATF)
("Ovation" or the "Company") announces that it will adopt semi-annual financial reporting under the
Canadian Securities Administrators' semi-annual reporting pilot program, in reliance on Coordinated
Blanket Order 51 - 933 Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers (the
"Blanket Order").
This news release is being filed pursuant to Coordinated Blanket Order 51 933 Exemptions to Permit
Semi-Annual Reporting for Certain Venture Issuers.
The initial interim period for which the Company does not intend to file an interim financial report and related
management's discussion and analysis ("MD&A") is the three- and nine-month period ended September
30, 2026.
The Company will continue to file audited annual financial statements and related MD&A, as well as interim
financial reports and related MD&A for the six-month period ending June 30 of each financial year. The
Company will not file interim financial reports or related MD&A for the three- and nine-month periods of its
financial year while it relies on the Blanket Order. The Company remains subject to all other continuous
disclosure obligations under applicable securities laws and the policies of the Canadian Securities
Exchange, including timely disclosure and material change reporting requirements. If the Company ceases
to rely on the Blanket Order, it will issue a news release indicating the next interim period for which it will
file an interim financial report and related MD&A.
"Moving to semi-annual reporting is expected to allow Ovation to reduce the cost and administrative burden
of quarterly reporting and focus our resources on commercial growth, while continuing to keep our
shareholders informed through our ongoing disclosure," said Terry Howlett, Chief Executive Officer.
ON BEHALF OF THE BOARD OF DIRECTORS
Terry Howlett
Chief Executive Officer and director
About Ovation Science Inc.
Ovation Science Inc., together with its wholly-owned subsidiary, Ovation Science USA Inc., is a research
and development company that develops topical and transdermal CBD/THC and other cannabinoid
products which are out-licensed and also distributed under Ovation's own brands, all powered by its
patented Invisicaretrademark skin delivery technology. Invisicare enhances the delivery of ingredients to and
through the skin and is protected by patents and proprietary formulations. With over 20 years of
pharmaceutical drug delivery experience, Ovation's management and science team have created a unique
pipeline of proprietary medical / wellness topical and transdermal products along with a line of anti-aging /
beauty formulas. Ovation earns revenues from royalties on licensees' sales and the sale of Invisicare, along
with revenue from its own product sales. Ovation has offices in Vancouver, Canada and Las Vegas, USA.
Stock symbols: CSE: OVAT / OTC: OVATF
Websites:
CORPORATE: www.ovationscience.com
WELLNESS: www.invibemd.com
BEAUTY: www.arlocbdbeauty.com
CORPORATE and LICENSING INQUIRIES
Terry Howlett: info@ovationscience.com
Cautionary Note Regarding Forward-Looking Information
This news release contains "forward-looking information" within the meaning of applicable Canadian
securities laws. Forward-looking information in this news release includes, but is not limited to, statements
regarding the Company's adoption of semi-annual financial reporting and continued reliance on the Blanket
Order, the interim periods for which the Company intends or does not intend to file interim financial reports
and related MD&A, the anticipated reduction in costs and administrative burden, and the Company's
intention to focus its resources on commercial growth. Words such as "will", "intend", "expect", "anticipate",
"plan" and similar expressions are intended to identify forward-looking information. Forward-looking
information is based on the Company's current expectations and assumptions, including that the Company
will continue to satisfy the eligibility conditions of the Blanket Order, that the Blanket Order will remain in
effect, and that the anticipated cost savings will be realized. Forward-looking information is subject to known
and unknown risks, uncertainties and other factors that may cause actual results to differ materially,
including the risk that the Company ceases to be eligible to rely on the Blanket Order, changes in securities
laws, regulatory policies or Canadian Securities Exchange policies, the risk that anticipated cost savings
are not realized, and the other risk factors described in the Company's continuous disclosure documents
available on SEDAR+ at www.sedarplus.ca. Readers are cautioned not to place undue reliance on forward-
looking information. The forward-looking information in this news release is made as of the date hereof,
and the Company undertakes no obligation to update or revise it, except as required by applicable securities
laws.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is
defined in the policies of the Canadian Securities Exchange) accepts responsibility for the
adequacy or accuracy of this news release.
© 2026 Canjex Publishing Ltd. All rights reserved.